TDC
PTCT icon

Thompson Davis & Co’s PTC Therapeutics PTCT Stock Holding History

Thompson Davis & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-34
Closed -$1K – 1143
2015
Q4 		$1K Hold
34
– – ﹤0.01% 1094
2015
Q3 		$1K Hold
34
– – ﹤0.01% 1094
2015
Q2 		$2K Hold
34
– – ﹤0.01% 1089
2015
Q1 		$2K Buy
+34
New +$2.07K ﹤0.01% 1087

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thompson Davis & Co's PTCT Position: Q1 2016 in Review

Thompson Davis & Co sold out of PTC Therapeutics (PTCT) in Q1 2016, closing a stake of 34 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in PTCT in Q1 2015 and held it in 4 quarters. The position peaked at $2K in Q2 2015. 119 funds tracked by Wall St. Rank hold PTCT as of Q1 2016.

  • Thompson Davis & Co reported no remaining PTC Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 34 PTC Therapeutics shares in Q1 2016, an estimated $1K.
  • Thompson Davis & Co first reported a position in PTC Therapeutics in Q1 2015 and held it in 4 quarters.
  • Thompson Davis & Co's PTC Therapeutics position peaked at $2K in Q2 2015.
  • 119 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.